Central serous chorioretinopathy (CSR) is an eye condition where fluid leakage from the choroid causes a detachment of the macula, the central part of the retina responsible for clear vision. Although the existing literature identifies corticosteroids as a risk factor for CSR, there is a growing interest in the use and impact of corticosteroids to treat CSR. The objective of this review is to evaluate the current evidence on the use of difluprednate, a topical ophthalmic medicine to treat inflammation and pain, for the treatment of CSR. The PubMed and Google Scholar databases were searched for all relevant English-language studies published from inception to October 2025, using the keywords "central serous chorioretinopathy" and "difluprednate". Despite the common consensus that steroids contribute to CSR development, many patients continue to be prescribed difluprednate in clinical practice after their CSR diagnosis. The short- and long-term effects of difluprednate for CSR treatment are not well-established. Future clinical trials can provide further insights into the rationale of difluprednate therapy for CSR treatment, especially because its use is contraindicated by existing evidence.
Chatterjee et al. (Mon,) studied this question.